Johnson & Johnson | JNJ | Long at $146.00
Johnson & Johnson 
JNJ is strong (but highly controversial) company with anticipated earnings growth on the horizon. With a P/E of 23x, steady dividend growth record, low debt, and expected increased cashflow, the future is optimistic for JNJ if they can stay out of the shady spotlight...
While the historical simple moving average I've selected suggests the stock is entering a downtrend on the daily chart, I'm going to go against this given the current price/position it is in. If the price can hold in $140's and then move up, there could be an early cup formation here. However, if the price drops below $140, that idea is out, and the near-term downtrend may be on. But the company, overall, is a personal buy-and-hold for the long-term ups and downs (unless new news points the company in a different direction). Thus, at $146.00,JNJ is in a personal buy-zone.
Target #1 = $157.00
Target #2 = $165.00
Target #3 = $170.00+
JNJ is strong (but highly controversial) company with anticipated earnings growth on the horizon. With a P/E of 23x, steady dividend growth record, low debt, and expected increased cashflow, the future is optimistic for JNJ if they can stay out of the shady spotlight...While the historical simple moving average I've selected suggests the stock is entering a downtrend on the daily chart, I'm going to go against this given the current price/position it is in. If the price can hold in $140's and then move up, there could be an early cup formation here. However, if the price drops below $140, that idea is out, and the near-term downtrend may be on. But the company, overall, is a personal buy-and-hold for the long-term ups and downs (unless new news points the company in a different direction). Thus, at $146.00,
JNJ is in a personal buy-zone.Target #1 = $157.00
Target #2 = $165.00
Target #3 = $170.00+
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.